**Supplementary Information**

***CNS Drugs***

**Sex differences in outcomes of intravenous thrombolysis in acute ischemic stroke patients with preadmission use of antiplatelets**

Roberta Noseda1, PhD, Federico Rea2,3, PhD, Alberto Pagnamenta4,5,6, MD, Pamela Agazzi7, MD, Giovanni Bianco7, MD, Shairin Sihabdeen7, MD, David Seiffge8, MD, Patrik Michel9, MD, Krassen Nedeltchev10, MD, Leo Bonati11, MD, Georg Kägi12, MD, Julien Niederhauser13, MD, Thomas Nyffeler14, MD, Andreas Luft15, MD, Susanne Wegener15, MD, Ludwig Schelosky16, MD, Friedrich Medlin17, MD, Biljana Rodic18, MD, Nils Peters19, MD, Susanne Renaud20, MD, Marie-Luise Mono21, MD, Emmanuel Carrera22, MD, Urs Fischer8,11, MD, Alessandro Ceschi1,4,23,24, MD, Carlo Walter Cereda7,23 MD.

1. Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland

2. Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy

3. National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy

4. Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland

5. Department of Intensive Care, Ente Ospedaliero Cantonale, Lugano, Switzerland

6. Division of Pneumology, University of Geneva, Geneva, Switzerland

7. Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland

8 University Hospital Bern, Department of Neurology, Bern, Switzerland

9 Lausanne University Hospital, Stroke Center, Neurology Service, Lausanne, Switzerland

10 Kantonsspital Aarau, Department of Neurology, Aarau, Switzerland

11 University Hospital Basel and University of Basel, Department of Neurology and Stroke Center, Basel, Switzerland

12 Kantonsspital St. Gallen, Department of Neurology, St. Gallen, Switzerland

13 Stroke Unit, Hopital Nyon, Switzerland

14 Luzerner Kantonsspital, Center of Neurology and Neurorehabilitation, Luzern, Switzerland

15 Universitätsspital Zürich, Neurology, Zürich, Switzerland

16 Kantonsspital Münsterlingen, Division of Neurology, Münsterlingen, Switzerland

17 HFR Fribourg, Stroke Unit, Division of Neurology, Fribourg, Switzerland

18 Kantonsspital Winterthur, Neurology, Winterthur, Switzerland

19 Hirslanden Hospital, Department of Neurology and Stroke Center, Zurich, Switzerland

20 Pourtalès Hospital, Division of Neurology, Neuchatel, Switzerland

21 Stadtspital Waid und Triemli, Stroke Unit, Zürich, Switzerland

22 Hôpitaux Universitaires de Genève, Department of Neurology, Geneva, Switzerland

23 Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland

24 Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland

***Corresponding author:***

Carlo Walter Cereda, MD, FAHA, FESO

Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale

via Tesserete 46, 6900 Lugano, Switzerland

Tel.: +41 91 811 66 91; email: carlo.cereda@eoc.ch

**Supplementary Table 1.** Details of the variables included in the regression models.

|  |  |  |
| --- | --- | --- |
| **Variable** | **Format** | **Transformation for the analyses** |
| Sex | Female (0) / Male (1) | Proportion of patients in the two groups |
| Age | years | Proportion of patients in the age groups:16-64; 65-74; 75-84; ≥85 |
| Preadmission use of antiplatelets | No (0) / Yes mono (1) / Yes dual (2) | Proportion of patients exposed to drugs |
| ComorbiditiesHypertensionHyperlipidaemiaDiabetesCADAFPre-stroke sICHPrevious stroke | No (0) / Yes (1) | Proportion of patients exposed to comorbidity |
| Smoking | No (0) / Yes (1) | Proportion of patients smoking |
| NIHSS at admission | 0-4 (0) / 5-10 (1) / 11-15 (2) / 16-21 (3) / ≥22 (4) | Proportion of patients in the groups |
| Pre-stroke disability | mRS score 0 (0) / mRS score 1 (1) / mRS score 2 (2) / mRS score 3 (3) / mRS score 4 (4) mRS score 5 (5) | Proportion of patients in the groups |
| In-hospital acute treatment with anticoagulants | No (0) / Yes (1) | Proportion of patients exposed to drugs |

*AF* atrial fibrillation, *CAD* coronary artery disease, *ICH* intracerebral haemorrhage, *mRS* modified Rankin Scale, *NIHSS* National Institutes of Health Stroke Scale.